Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Field Test
Sponsor: National Aeronautics and Space Administration (NASA)
This PHASE2 trial investigates Motion Sickness, Space and Motion Simulation and is currently actively recruiting participants. National Aeronautics and Space Administration (NASA) leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Aeronautics and Space Administration (NASA)
- Repurposed Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .